10-K: Drugs Made In America Acquisition Corp. 10-K Analysis

Drugs Made In America Acquisition Corp. reports management turnover, material internal control weaknesses, and a potential $1 billion de-SPAC target.

Summary

• The company is a special purpose acquisition company (SPAC) with no operations and nominal assets, currently seeking an initial business combination.
• As of December 31, 2025, the company reported net income of $5,940,643, primarily driven by interest earned on the trust account.
• The company faces substantial doubt regarding its ability to continue as a going concern due to its limited cash and the need to complete a business combination within a prescribed timeframe.
• A letter of intent has been signed with Power Analytics Global Corp. for a potential de-SPAC transaction with an anticipated valuation of approximately $1.0 billion.
• The company has experienced significant management turnover, including the resignation of the former CEO and CFO, and the appointment of new leadership in early 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to material internal control weaknesses, management turnover following a financial dispute, and the company's status as a going concern.

Positives

• The company has secured an interim financing commitment of $500,000 to support operations and transaction costs.
• A letter of intent has been signed with a potential target, Power Analytics Global Corp., indicating progress toward a business combination.
• The trust account remains intact with approximately $241.3 million as of March 6, 2026.

Negatives

• The company reported material weaknesses in internal control over financial reporting, specifically regarding segregation of duties and related party transaction reviews.
• The former CEO and sponsor were involved in a financial dispute regarding the withdrawal of funds from an affiliate's account, leading to management changes.
• The company has a working capital deficit of $363,981 as of December 31, 2025.
• The sponsor has defaulted on its share subscription receivable, impacting the company's liquidity.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• There is no guarantee that the proposed business combination with Power Analytics Global Corp. will be completed.
• The company may fail to complete a business combination within the required timeframe, leading to liquidation.
• The company faces intense competition from other SPACs and private investors for suitable acquisition targets.
• The company's internal control weaknesses could lead to errors or fraud in financial reporting.

Future Outlook

The company intends to focus on completing a business combination with Power Analytics Global Corp. or another target in the AI, pharmaceutical, or technology sectors, while seeking to extend its combination period to April 2027.

Management Comments

• Management acknowledges material weaknesses in internal controls and plans to implement remediation steps.
• The new management team is focused on completing a business combination and stabilizing operations following the departure of the former CEO.

Industry Context

StockSavvy.ai notes that this filing reflects the heightened volatility and governance challenges currently facing the SPAC market, particularly regarding sponsor reliability and the pressure to complete transactions before liquidation deadlines.

Comparison to Industry Standards

• The company's structure as a Cayman Islands exempted company is standard for SPACs.
• The reliance on sponsor loans for working capital is common, though the sponsor's default on obligations is a significant deviation from standard performance.
• The proposed $1 billion valuation for the target is consistent with large-cap SPAC targets in the technology sector.

Management Changes

Corporate Governance

Legal Proceedings

• None currently pending.

Related Party Transactions

• Sponsor defaulted on share subscription receivable.
• Former CEO and spouse entered into a sponsor standstill and cooperation agreement.
• Company issued an interim convertible note to BV Advisory Partners, LLC.

Stakeholder Impact

• Shareholders face uncertainty regarding the completion of a business combination and the potential for liquidation.
• The sponsor's default on financial obligations may impact the company's ability to fund operations.

Next Steps

• Hold an extraordinary general meeting on April 27, 2026, to vote on the extension of the combination period.
• Continue due diligence on the potential business combination with Power Analytics Global Corp.
• Implement remediation steps for identified material weaknesses in internal controls.

Key Dates

Recommendation

The combination of material internal control weaknesses, management turnover, sponsor default, and going concern issues presents significant risks that outweigh the potential upside of the proposed business combination.

Keywords

SPAC, de-SPAC, Power Analytics Global Corp., business combination, initial public offering, Cayman Islands, Nasdaq